



Rupatadine during breastfeeding: Two case reports

Shira Shalit¹, Sharon Yehuda¹, Tal De-Haan¹, Ariela Hazan¹, Nofar Benassayag Kaduri¹, Elkana Kohn¹, Matitiah Berkovitch^{1,2}, and Maya Berlin¹

¹*Clinical Pharmacology and Toxicology Unit; Drug Consultation Center, Shamir Medical Center (Assaf Harofeh), Zerifin; Israel*

²*The Andy Lebach Chair of Clinical Pharmacology and Toxicology, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Israel*


Introduction

Rupatadine is a second generation selective H₁-antagonist and platelet activating factor (PAF) antagonist used to treat allergic rhinitis and urticaria.


It is generally well tolerated, with somnolence, headache, and dry mouth among the most commonly reported adverse effects.

There is currently no data regarding the safety use during breastfeeding or the extent of its transfer into human milk.

CASE No. 1



CASE No. 2





Rupatadine during breastfeeding: Two case reports



Conclusions

In both cases maternal exposure to rupatadine during lactation demonstrated no effect on child development outcomes.

The variability observed in milk production between the two cases may suggest a potential dose-dependent effect of rupatadine on lactation.